Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HK1 | P19367 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | GALK1 | P51570 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridan SCHEMBL29446489 | 0.97 | MAPT (0.65) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL20594012 | 0.97 | MAPT (0.65) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL183367 | 0.97 | MAPT (0.65) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL29405807 | 0.97 | MAPT (0.65) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL28832553 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL29006126 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E | |
| SCHEMBL4571016 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL29020974 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL10813635 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E | |
| Acridan SCHEMBL28268824 | 0.94 | MAPT (0.62) | MAPTMEN1KMT2ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104411688-B | Synthesis of acridinium compounds from N-alkylation of 9,10-dihydroacridine | 西门子医疗保健诊断公司 | 2019-01-08 | — | — | CN | disclosed |
| EP-2872489-B1 | SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9512080-B2 | Synthesis of acridinium compounds by N-alkylation of acridans | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150197491-A1 | SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2872489-A1 | SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS | Siemens Healthcare Diagnostics Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014011762-A1 | SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS | SIEMENS HEAL THCARE DIAGNOSTICS INC. (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197491-A1 | SYNTHESIS OF ACRIDINIUM COMPOUNDS BY N-ALKYLATION OF ACRIDANS | ACR, MCL1, MGMT | MAPT 4190/4885MEN1 983/4885KMT2A 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.